Prostate Cancer Clinical Trial
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. Implant radiation therapy kills tumor cells by placing material such as radioactive iodine directly into or near a tumor. Giving leuprolide and bicalutamide together with implant radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving leuprolide and bicalutamide together with implant radiation therapy and to see how well it works in treating patients with locally recurrent prostate cancer after external-beam radiation therapy.
Full Description
OBJECTIVES:
Determine the feasibility and patient tolerance of interstitial brachytherapy combined with androgen-deprivation therapy for patients with locally recurrent prostate cancer after prior external-beam irradiation.
Determine the toxicity of interstitial brachytherapy combined with androgen-deprivation therapy in these patients.
Determine the tumor response to interstitial brachytherapy combined with androgen-deprivation therapy in these patients.
OUTLINE: Patients receive neoadjuvant therapy comprising leuprolide acetate intramuscularly for 3 months and oral bicalutamide once daily for 30 days, beginning on the first day of leuprolide acetate administration. Patients then undergo interstitial brachytherapy implantation with I-125. Following brachytherapy, patients receive adjuvant leuprolide acetate every 3 months for an additional 6 months.
Quality of life is assessed at baseline and at every treatment and follow-up visit.
After completion of study therapy, patients are followed every 3 months for 2 years, every to 4-6 months for 3 years, and then annually thereafter.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Biopsy-proven adenocarcinoma of the prostate
Locally recurrent disease, defined by digital rectal examination and/or rising prostate-specific antigen (PSA)
No evidence of nodal or distant metastasis (i.e., N0, M0) on physical examination, bone scan, or CT scan of the pelvis
Clinical stage T1c-T3a disease at the time of recurrence
PSA < 10 ng/mL
Prostate volume by transrectal ultrasonography < 60 cc
Received prior external beam radiotherapy
PATIENT CHARACTERISTICS:
ECOG performance status 0-2
WBC ≥ 3,000/μL
Platelet count ≥ 90,000/μL
Hemoglobin ≥ 10 g/dL
Alkaline phosphatase < 2 times normal
AST < 2 times normal
Normal prothrombin time and partial thromboplastin time
No significant obstructive urinary symptoms (AUA score ≤ 16)
No contraindication for general anesthesia
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No prior transurethral resection of the prostate
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Scottsdale Arizona, 85259, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.